Microscopic Colitis

Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by chronic, watery, non-bloody diarrhea. While the colonic mucosa appears endoscopically and radiologically normal, diagnosis is established strictly via histological evaluation of colonic mucosal biopsies. It encompasses two primary subtypes: collagenous colitis (CC) and lymphocytic colitis (LC).

The precise cause is multifactorial, involving an abnormal immune response to luminal antigens in genetically susceptible individuals. Key factors include:

• Immune Dysregulation: Association with autoimmune disorders.


• Gut Microbiota Dysbiosis: Altered mucosal barrier function.


• Drug-Induced: Strongly associated with certain medications (e.g., NSAIDs, PPIs, SSRIs).


• Lifestyle: Cigarette smoking significantly increases risk.

Infiltration of inflammatory cells occurs in the colonic lamina propria.

• Collagenous Colitis: Characterized by a thickened subepithelial collagen band (>10 μm) beneath the surface epithelium, accompanied by epithelial damage and intraepithelial lymphocytosis.


• Lymphocytic Colitis: Marked by a significant increase in intraepithelial lymphocytes (IELs) (≥20 per 100 epithelial cells) with a normal subepithelial collagen band. In both subtypes, mucosal inflammation impairs sodium and water absorption, leading to secretory diarrhea.

• Prevalence: Approximately 100 cases per 100,000 individuals in Western countries.
• Age: Primarily affects older adults, with a median age of 60 to 65 years at diagnosis.
• Gender: Strong female predominance, particularly for collagenous colitis (female-to-male ratio up to 9:1).

• Female gender
• Age > 50 years
• Cigarette smoking
• Concomitant autoimmune diseases (e.g., celiac disease, thyroiditis, rheumatoid arthritis)
• Chronic use of trigger medications (NSAIDs, PPIs, SSRIs, beta-blockers)

Physical examination is usually unremarkable. Severe cases may demonstrate:

• Vital Signs: Tachycardia or orthostatic hypotension (secondary to dehydration).


• Abdomen: Mild, diffuse abdominal tenderness without rigidity, guarding, or rebound.


• Skin: Poor skin turgor and dry mucous membranes (dehydration).

• A. Clinical Assessment: Comprehensive history focusing on onset, stool characteristics, and medication exposure.
• B. Laboratory Testing: Initial screens to rule out infection, celiac disease, or systemic inflammation.
• C. Imaging Studies: Colonoscopy with biopsy is the gold standard; radiologic imaging is of limited utility.
• D. Functional Tests: Fecal calprotectin may be normal or mildly elevated.
• E. Biopsy Findings: Confirms diagnosis by showing lymphocytic infiltration (LC) or a thickened subepithelial collagen band (CC).
• F. Genetic Testing: Not routinely indicated, though HLA-DQ2/DQ8 typing may be done if celiac disease is suspected.
• G. Differential Diagnosis: Essential to rule out irritable bowel syndrome (IBS-D) and classical IBD.

Stool Culture and C. difficile PCR

• Type: Stool Test


• Purpose: Exclude infectious colitis causes.


• Expected Findings: Negative for bacterial pathogens and toxins.


• Interpretation: Confirms non-infectious etiology. Anti-tissue Transglutaminase (tTG) IgA


• Type: Blood Test


• Purpose: Screen for comorbid Celiac Disease.


• Expected Findings: Normal (<15 U/mL).


• Interpretation: Elevated levels warrant duodenal biopsy.

• Colonoscopy with Segmental Biopsies: Essential for diagnosis. Endoscopy typically reveals structurally normal mucosa. Biopsies must be taken from multiple colonic segments (ascending, transverse, descending colon) as changes can be patchy.

• Irritable Bowel Syndrome with Diarrhea (IBS-D): Lacks biopsy-proven histopathological mucosal inflammation.
• Celiac Disease: Distinguished by duodenal biopsy showing villous atrophy and positive serologies (tTG-IgA).
• Crohn’s Disease / Ulcerative Colitis: Show macroscopically visible ulcers, mucosal friability, and distinct architectural distortion.

• Severe dehydration and electrolyte depletion (hypokalemia, hyponatremia)
• Significant weight loss and malnutrition
• Fecal incontinence causing severe quality-of-life impairment
• Extremely rarely, spontaneous colonic perforation

The prognosis is highly favorable. MC is a benign condition without an increased risk of colorectal cancer. Most patients respond well to budesonide therapy, though clinical relapse occurs in up to 40% of cases after stopping treatment, sometimes requiring low-dose maintenance therapy.

• Avoidance of known trigger medications.
• Cessation of tobacco use.

The following homeopathic remedies have been historically indicated for symptoms associated with Microscopic Colitis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Microscopic Colitis.